<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00429416</url>
  </required_header>
  <id_info>
    <org_study_id>04U.115</org_study_id>
    <secondary_id>2003-68</secondary_id>
    <nct_id>NCT00429416</nct_id>
  </id_info>
  <brief_title>Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation</brief_title>
  <official_title>A Phase I/II Study of Llme Treated Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine if an experimental agent, LLME can
      decrease the incidence and severity of Graft-Versus-Host-Disease (GVHD) following blood
      (hematopoietic) stem cell transplantation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We believe that the risks of allogeneic transplant can be drastically reduced if the
      following criteria can be met: (1) consistent engraftment, (2) little or no GVHD with the
      ability to rapidly withdraw immune suppression, (3) rapid recovery of CD4 counts to levels
      greater than 200 cells/micro liter. Our prior (ongoing) trial attempts to address how LLME
      treated T cells given as donor lymphocyte infusion (DLI) can address points 2 and 3 above.
      The current study addresses how treatment of the CD34- fraction of the graft attempts to
      address points 1 and 2 (and to a lesser extent point 3) above. We believe that if these
      points can be consistently achieved that the mortality of allogeneic HSCT may be reduced to
      levels more akin to those of autologous HSCT. We propose to test the hypothesis that
      LLME-treated T cells will be safe with regard to reducing GVHD or other infusion related
      toxicities and that their administration as part of the transplant will facilitate
      engraftment. We believe that this approach will ultimately be an important step in a variety
      of transplant settings ranging from matched siblings to haplodisparate donors.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of CD34+ Stem Cell Infusions Followed by LLME as Measured by 100-Day Mortality</measure>
    <time_frame>Through 100 days post-transplant or death</time_frame>
    <description>Determine the safety of CD34+ stem cell infusions followed by the LLME treated CD34- fraction. This includes monitoring the patients for any side effects associated with the LLME treated cell infusion or any other unexpected adverse events.
This regimen will be gauged as to its safety using 100 day mortality as the measured endpoint. Deaths from all causes will be included.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Engraftment of Non-Myeloablative Transplants</measure>
    <time_frame>Through 30 days post-transplant</time_frame>
    <description>Determine the engraftment rate of non-myeloablative transplants using CD34+ stem cells and LLME treated CD34- products.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grade II-IV Acute Graft-Versus-Host-Disease (GVHD)</measure>
    <time_frame>Through 24 months post-treatment</time_frame>
    <description>Determine the incidence of grade II-IV acute GVHD after administration of grafts when combined with Cyclosporine/Mycophenolate Mofetil for GVHD prophylaxis. GVHD assessments occur daily as an in patient and at each out patient visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Serious Infectious Complications</measure>
    <time_frame>Through 3 months post-transplant</time_frame>
    <description>Determine the rate of serious infectious complications. A serious infection will be defined as any requiring hospitalization or parenteral therapy.
CD4 counts will be measured monthly for the first 3 months after transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Achieve a CD4 Count &gt; 200/Micro-liters</measure>
    <time_frame>Through 60 Days Post Transplant</time_frame>
    <description>Determine the number of patients who achieve a CD4 count &gt; 200/micro-liters by 60 days after transplant.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>LLME to Decrease GVHD Following HSC T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To determine if an experimental agent, LLME, can decrease the incidence and severity of Graft-Versus-Host-Disease (GVHD) following hematopoietic stem cell transplantation (HSCT).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-leucyl-L-leucine Methyl Ester (LLME)</intervention_name>
    <description>Infusion of L-leucyl-L-leucine methyl ester (LLME) treated donor white blood cells</description>
    <arm_group_label>LLME to Decrease GVHD Following HSC T</arm_group_label>
    <other_name>LLME</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine 30 mg/m2 prior to HSCT infusion</description>
    <arm_group_label>LLME to Decrease GVHD Following HSC T</arm_group_label>
    <other_name>fludarabine phosphate</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Cytarabine 2gm/m2 prior to HSCT infusion</description>
    <arm_group_label>LLME to Decrease GVHD Following HSC T</arm_group_label>
    <other_name>cytosine arabinoside</other_name>
    <other_name>Ara-C</other_name>
    <other_name>Arabinofuranosyl Cytidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 1gm/m2 prior to HSCT infusion</description>
    <arm_group_label>LLME to Decrease GVHD Following HSC T</arm_group_label>
    <other_name>Endoxan</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Procytox</other_name>
    <other_name>Revimmune</other_name>
    <other_name>cytophosphane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Tacrolimus given before and after HSCT infusion</description>
    <arm_group_label>LLME to Decrease GVHD Following HSC T</arm_group_label>
    <other_name>FK-506</other_name>
    <other_name>Fujimycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>Mesna 1gm/m2/day given prior to HSCT infusion.</description>
    <arm_group_label>LLME to Decrease GVHD Following HSC T</arm_group_label>
    <other_name>Uromitexan</other_name>
    <other_name>Mesnex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)</intervention_name>
    <description>GM-CSF given post HSCT infusion</description>
    <arm_group_label>LLME to Decrease GVHD Following HSC T</arm_group_label>
    <other_name>GM-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hematopoietic stem cell transplantation (HSCT)</intervention_name>
    <description>CD34 selected allogeneic stem cell infusion with 5x104/kg untreated T cells</description>
    <arm_group_label>LLME to Decrease GVHD Following HSC T</arm_group_label>
    <other_name>HSCT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be &gt; 18 years of age, with no upper age limit.

          -  Patients must have an ECOG performance status of 0 or 1.

          -  Any patient with a hematologic malignancy which is unlikely to be cured by
             conventional treatment is eligible for this study.

          -  Patients for whom a disease specific protocol exists will be transplanted on those
             protocols as discussed in the introduction.

          -  Patients who have had prior autografts may be treated on this protocol.

          -  Patients must have adequate physical function as measured by the following criteria:

          -  Cardiac: Asymptomatic or, if symptomatic, then left ventricular ejection fraction at
             rest must be &gt;40%.

          -  Hepatic: Aspartate transaminase (AST) micro 3x the upper limits of normal and total
             serum bilirubin &lt; 2.5 mg/dL. Patients with a higher bilirubin from &quot;benign conditions&quot;
             such as Gilbert's disease may still be eligible for the study.

          -  Renal: Serum creatinine within the normal range or if creatinine outside normal range
             then creatinine clearance &gt; 60 ml/min/1.73m2. Serum creatinine must be less than or
             equal to 2.0 mg/dl.

          -  Pulmonary: Asymptomatic or, if symptomatic, DLCO (diffusion capacity) &gt; 45% of
             predicted (corrected for hemoglobin)

          -  The patient or guardian(s) must be able to give informed consent to the study.

          -  Patient must have a suitable donor who is identical for HLA (human leukocyte antigens)
             -A, -B, -C, -DR. Single antigen mismatches for HLA-A, -B, -C, -DR are also permitted.
             Donors obtained through the National Marrow Donor Program (NMDP) will follow NMDP
             guidelines.

        Exclusion Criteria:

          -  Patients who are eligible for a standard myeloablative transplant and for whom a
             standard myeloablative transplant is preferable will not be treated on this protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Wagner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University`</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.KimmelCancerCenter.org</url>
    <description>Kimmel Cancer Center at Thomas Jefferson University, an NCI-Designated Cancer Center</description>
  </link>
  <link>
    <url>http://www.JeffersonHospital.org/</url>
    <description>Thomas Jefferson University Hospital</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2007</study_first_submitted>
  <study_first_submitted_qc>January 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2007</study_first_posted>
  <results_first_submitted>July 19, 2013</results_first_submitted>
  <results_first_submitted_qc>October 14, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 10, 2013</results_first_posted>
  <last_update_submitted>October 19, 2016</last_update_submitted>
  <last_update_submitted_qc>October 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematologic Malignancies</keyword>
  <keyword>GVHD</keyword>
  <keyword>Graft-Versus-Host-Disease</keyword>
  <keyword>LLME</keyword>
  <keyword>CD34+ stem cell infusions</keyword>
  <keyword>CD34- fraction</keyword>
  <keyword>Cyclosporine</keyword>
  <keyword>Mycophenolate Mofetil</keyword>
  <keyword>HSCT</keyword>
  <keyword>Hematopoietic stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>LLME to Decrease GVHD Following HSC T</title>
          <description>To determine if an experimental agent, L-leucyl-L-leucine Methyl Ester (LLME), can decrease the incidence and severity of Graft-Versus-Host-Disease (GVHD) following hematopoietic stem cell transplantation (HSCT).
Treatment Outline:
Day -6: Fludarabine 30 mg/m2 IV, Cytarabine 2 gm/m2 IV Day -5: Fludarabine 30 mg/m2 IV, Cyclophosphamide 1 gm/m2 IV, Mesna 1 gm/m2 IV Day -4: Fludarabine 30 mg/m2 IV, Cytarabine 2 gm/m2 IV, Mesna 1 gm/m2 IV Day -3: Fludarabine 30 mg/m2 IV, Cyclophosphamide 1 gm/m2 IV, Mesna 1 gm/m2 IV Day -2: Fludarabine 30 mg/m2 IV, Cytarabine 2 gm/m2 IV, Mesna 1 gm/m2 IV Day -1: Rest day Day 0: CD34 selected allogeneic stem cell infusion with 5x104/kg untreated T cells Day 1: Infusion of LLME treated donor CD34 â€“ cells</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LLME to Decrease GVHD Following HSC T</title>
          <description>To determine if an experimental agent, LLME, can decrease the incidence and severity of Graft-Versus-Host-Disease (GVHD) following hematopoietic stem cell transplantation (HSCT).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.65" spread="9.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety of CD34+ Stem Cell Infusions Followed by LLME as Measured by 100-Day Mortality</title>
        <description>Determine the safety of CD34+ stem cell infusions followed by the LLME treated CD34- fraction. This includes monitoring the patients for any side effects associated with the LLME treated cell infusion or any other unexpected adverse events.
This regimen will be gauged as to its safety using 100 day mortality as the measured endpoint. Deaths from all causes will be included.</description>
        <time_frame>Through 100 days post-transplant or death</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LLME to Decrease GVHD Following HSC T</title>
            <description>To determine if an experimental agent, LLME, can decrease the incidence and severity of Graft-Versus-Host-Disease (GVHD) following hematopoietic stem cell transplantation (HSCT).</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of CD34+ Stem Cell Infusions Followed by LLME as Measured by 100-Day Mortality</title>
          <description>Determine the safety of CD34+ stem cell infusions followed by the LLME treated CD34- fraction. This includes monitoring the patients for any side effects associated with the LLME treated cell infusion or any other unexpected adverse events.
This regimen will be gauged as to its safety using 100 day mortality as the measured endpoint. Deaths from all causes will be included.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Engraftment of Non-Myeloablative Transplants</title>
        <description>Determine the engraftment rate of non-myeloablative transplants using CD34+ stem cells and LLME treated CD34- products.</description>
        <time_frame>Through 30 days post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LLME to Decrease GVHD Following HSC T</title>
            <description>To determine if an experimental agent, LLME, can decrease the incidence and severity of Graft-Versus-Host-Disease (GVHD) following hematopoietic stem cell transplantation (HSCT).</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Engraftment of Non-Myeloablative Transplants</title>
          <description>Determine the engraftment rate of non-myeloablative transplants using CD34+ stem cells and LLME treated CD34- products.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Grade II-IV Acute Graft-Versus-Host-Disease (GVHD)</title>
        <description>Determine the incidence of grade II-IV acute GVHD after administration of grafts when combined with Cyclosporine/Mycophenolate Mofetil for GVHD prophylaxis. GVHD assessments occur daily as an in patient and at each out patient visit.</description>
        <time_frame>Through 24 months post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LLME to Decrease GVHD Following HSC T</title>
            <description>To determine if an experimental agent, LLME, can decrease the incidence and severity of Graft-Versus-Host-Disease (GVHD) following hematopoietic stem cell transplantation (HSCT).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Grade II-IV Acute Graft-Versus-Host-Disease (GVHD)</title>
          <description>Determine the incidence of grade II-IV acute GVHD after administration of grafts when combined with Cyclosporine/Mycophenolate Mofetil for GVHD prophylaxis. GVHD assessments occur daily as an in patient and at each out patient visit.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Developed grade II-IV GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Developed cGVHD (Chronic GVHD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Serious Infectious Complications</title>
        <description>Determine the rate of serious infectious complications. A serious infection will be defined as any requiring hospitalization or parenteral therapy.
CD4 counts will be measured monthly for the first 3 months after transplant.</description>
        <time_frame>Through 3 months post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LLME to Decrease GVHD Following HSC T</title>
            <description>To determine if an experimental agent, LLME, can decrease the incidence and severity of Graft-Versus-Host-Disease (GVHD) following hematopoietic stem cell transplantation (HSCT).</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Serious Infectious Complications</title>
          <description>Determine the rate of serious infectious complications. A serious infection will be defined as any requiring hospitalization or parenteral therapy.
CD4 counts will be measured monthly for the first 3 months after transplant.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Achieve a CD4 Count &gt; 200/Micro-liters</title>
        <description>Determine the number of patients who achieve a CD4 count &gt; 200/micro-liters by 60 days after transplant.</description>
        <time_frame>Through 60 Days Post Transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LLME to Decrease GVHD Following HSC T</title>
            <description>To determine if an experimental agent, LLME, can decrease the incidence and severity of Graft-Versus-Host-Disease (GVHD) following hematopoietic stem cell transplantation (HSCT).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Achieve a CD4 Count &gt; 200/Micro-liters</title>
          <description>Determine the number of patients who achieve a CD4 count &gt; 200/micro-liters by 60 days after transplant.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>&quot;Other Adverse Events&quot; were not collected/assessed</desc>
      <group_list>
        <group group_id="E1">
          <title>LLME to Decrease GVHD Following HSC T</title>
          <description>To determine if an experimental agent, LLME, can decrease the incidence and severity of Graft-Versus-Host-Disease (GVHD) following hematopoietic stem cell transplantation (HSCT).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Bone marrow cellularity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pancyptopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Progressive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Fevers</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Prostatic obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Opportunistic infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Bladder obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Renal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Wagner, MD</name_or_title>
      <organization>Thomas Jefferson University</organization>
      <phone>215-955-8874</phone>
      <email>John.Wagner@jefferson.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

